Pure Global
NCT06249256

An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells

An Exploratory Study on the Treatment of Advanced Solid Tumors by Secretory PD1 Nanoantibody Targeting Mesothelin Fast CAR T Cells
Shanghai Cell Therapy Group Co.,Ltd·Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
Fast CAR T cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Shanghai Cell Therapy Group Co.,Ltd
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2023
End date
Dec 31, 2026
Enrollment
12 participants
Primary outcome

Dose-limiting toxicity(DLT)

Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and
 tolerability of fast autologous mesothelin (MSLN)-targeted chimeric antigen receptor
 (MSLN-CAR) T cells secreting PD-1 nanobodies in patients with solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06249256
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06249256 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Cell Therapy Group Co.,Ltd and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.